The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi ...

At close: 14 March at 8:17:05 CET ...

Newron Pharma's sodium channel blocker evenamide, which had encouraging phase 2/3 data earlier this year, and Neurocrine Biosciences/Nxera Pharma's muscarinic M4 agonist NBI-1117568, which ...

Jefferies analyst Miyabi Yamakita maintained a Buy rating on Sosei Group (SOLTF – Research Report) today and set a price target of Yen2,000.00.

The finalists for the 2025 Cambridge Independent Science and Technology Awards can now be revealed. It follows an extensive ...

The rise of artificial intelligence (AI), digitalisation, wider adoption of tools for marketing automation, and numerous other technologies have significantly reshaped the world of pharma for the ...

Drugmakers agree to participate in second round of price negotiations All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...

Exclusive: Gates warns White House he can't fill shortfalls in US global health funding Bill Gates is personally lobbying Trump administration officials to keep funding health programs worldwide ...

All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma ...

Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 14,337.75 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments ...